Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma

The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro, Natalia, Molist, Carla, Sansa-Girona, Júlia, Zarzosa, Patricia, Gallo-Oller, Gabriel, Pons, Guillem, Magdaleno, Ainara, Guillén, Gabriela, Hladun, Raquel, Garrido, Marta, Segura, Miguel F., Hontecillas-Prieto, Lourdes, de Álava, Enrique, Ponsati, Berta, Fernández-Carneado, Jimena, Almazán-Moga, Ana, Vallès-Miret, Mariona, Farrera-Sinfreu, Josep, de Toledo, Josep Sánchez, Moreno, Lucas, Gallego, Soledad, Roma, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553833/
https://www.ncbi.nlm.nih.gov/pubmed/36221013
http://dx.doi.org/10.1007/s00018-022-04557-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553833/
https://www.ncbi.nlm.nih.gov/pubmed/36221013
http://dx.doi.org/10.1007/s00018-022-04557-y

Ejemplares similares